Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Fineline Cube Feb 3, 2026
Company Deals

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases

Fineline Cube Feb 3, 2026
Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Fineline Cube Feb 2, 2026
Company Deals

Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia

Fineline Cube Feb 2, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Fineline Cube Feb 3, 2026
Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Fineline Cube Feb 3, 2026
Company Medical Device

Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province

Fineline Cube Nov 4, 2024

China-based in vitro fertilization (IVF) specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has announced...

Company Deals

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital

Fineline Cube Nov 4, 2024

Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing...

Company Drug

Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH

Fineline Cube Nov 4, 2024

Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...

Company Drug

Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes

Fineline Cube Nov 4, 2024

China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab...

Company Drug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study

Fineline Cube Nov 4, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...

Company Deals

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures

Fineline Cube Nov 4, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...

Policy / Regulatory

China’s CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Nov 4, 2024

The Center for Drug Evaluation (CDE) in China has announced its 88th batch of reference...

Company

AstraZeneca’s China President Leon Wang Confirmed to Assist in Investigation Amid Fraud Allegations

Fineline Cube Nov 3, 2024

On October 29, 2024, just hours after celebrating a business school anniversary on social media,...

Company Drug

Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial

Fineline Cube Nov 2, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...

Company Drug

Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial

Fineline Cube Nov 2, 2024

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Compound Sodium Lactate Ringer’s Injection

Fineline Cube Nov 2, 2024

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products...

Policy / Regulatory

National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate

Fineline Cube Nov 1, 2024

The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...

Company

MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector

Fineline Cube Nov 1, 2024

US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...

Company

Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024

Fineline Cube Nov 1, 2024

US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...

Company Deals

AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer

Fineline Cube Nov 1, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Drug

CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume

Fineline Cube Nov 1, 2024

The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...

Company Drug

AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China

Fineline Cube Nov 1, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...

Company Drug

Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA

Fineline Cube Nov 1, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Fineline Cube Nov 1, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company

Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance

Fineline Cube Nov 1, 2024

US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...

Posts pagination

1 … 226 227 228 … 618

Recent updates

  • Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation
  • Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China
  • SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
  • Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
  • Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation

Company Drug

Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China

Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.